Zacks Investment Research cut shares of Tyme Technologies (NASDAQ:TYME) from a buy rating to a hold rating in a research report report published on Friday.
According to Zacks, “Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body’s immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. “
Several other research analysts have also issued reports on the company. BidaskClub lowered Tyme Technologies from a sell rating to a strong sell rating in a research report on Friday, August 10th. Canaccord Genuity set a $10.00 target price on Tyme Technologies and gave the company a buy rating in a research report on Tuesday, July 31st. Finally, HC Wainwright reaffirmed a buy rating and set a $9.50 target price on shares of Tyme Technologies in a research report on Thursday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. Tyme Technologies has an average rating of Hold and a consensus price target of $7.31.
A number of institutional investors have recently bought and sold shares of TYME. Rhumbline Advisers purchased a new stake in Tyme Technologies during the 2nd quarter valued at about $110,000. Schwab Charles Investment Management Inc. purchased a new stake in Tyme Technologies during the 2nd quarter valued at about $248,000. Bank of New York Mellon Corp purchased a new stake in Tyme Technologies during the 2nd quarter valued at about $267,000. Perkins Capital Management Inc. grew its stake in Tyme Technologies by 330.0% during the 2nd quarter. Perkins Capital Management Inc. now owns 101,050 shares of the company’s stock valued at $319,000 after purchasing an additional 77,550 shares during the last quarter. Finally, Northern Trust Corp purchased a new stake in Tyme Technologies during the 2nd quarter valued at about $1,181,000. Institutional investors and hedge funds own 11.13% of the company’s stock.
Tyme Technologies Company Profile
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Recommended Story: Inflation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.